Pulmatrix Q1 net loss narrows, clinical development on hold

Pulmatrix

15/05/2026 13:27

Overview

U.S. biopharmaceutical firm's Q1 net loss per share was $0.32, clinical development on hold

Company announced merger agreement with Eos SENOLYTIX, expected to close in Q3 2026

General and administrative expenses fell yr/yr due to lower SEC filing costs

Outlook

Pulmatrix expects proposed merger with Eos SENOLYTIX to close in Q3 2026

Company says all clinical development is on hold while it seeks to license or monetize assets

Pulmatrix anticipates cash position is sufficient to fund operations through expected merger closing

Result Drivers

CLINICAL DEVELOPMENT ON HOLD - All clinical development paused as co seeks to license or monetize clinical assets

LOWER ADMINISTRATIVE COSTS - General and administrative expenses fell yr/yr due to higher costs in prior year related to SEC filing preparation

CAPITAL RAISE - Co secured $1 mln in gross proceeds from private placement of preferred stock

Company press release: ID:nPn15rp9pa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.32


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)